Application of New Data in B-Cell Malignancies From ASCO and EHA 2020

ASCO 2020 Virtual Meeting/May 29-31, 2020
EHA 2020 Virtual Meeting/June 11-21, 2020
Lydia Scarfò, MD discusses key data in B-cell malignancies from EHA and ASCO 2020.
Lydia Scarfò, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 877 KB
Released: July 16, 2020

Acknowledgements

Supported by an educational grant from
AstraZeneca

Related Content

Downloadable slideset from a local live webinar developed by lymphoma experts with guidance on the management of indolent lymphomas

Elizabeth Brém, MD Christopher R. Flowers, MD, MS Released: June 21, 2022

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 17, 2022

Phase II trial shows high response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 chemotherapy in newly diagnosed FLT3-mutated AML, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings